CORCEPT THERAPEUTICS

Company snapshot

CORCEPT THERAPEUTICS maintains 67 tracked programs across Nonalcoholic Steatohepatitis (NASH), Amyotrophic Lateral Sclerosis, Cushing's Syndrome, Cushing Syndrome, Hepatic Impairment, Hypercortisolism, Antipsychotic-induced Weight Gain (AIWG), Endogenous Cushing Syndrome, Gynecological Cancers, Metastatic Breast Cancer, Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer. Momentum sco

• 1 approved product(s) across US/EU regulatory metadata.
• 67 active pipeline program(s) linked via ClinicalTrials.gov.
• 120 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for CORCEPT THERAPEUTICS. Not investment advice.

• Peer + 0 momentum

  HALOZYME THERAPEUTICS

  TA overlap score 29

• Peer + 0 momentum

  Oncolytics Biotech

  TA overlap score 24.6

• Peer + 0 momentum

  Galmed Pharmaceuticals

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for CORCEPT THERAPEUTICS.

1. Jun 8, 2026 Clinical update

   CORT125134-557 — Phase 2

2. Jun 8, 2026 Clinical update

   CORT125134-556 — Phase 3

3. Jun 8, 2026 Clinical update

   CORT125134-452 — Phase 3

4. Jun 8, 2026 Clinical update

   CORT113176-652 — Phase 2

5. Jun 8, 2026 Clinical update

   CORT125281-600 — Phase 1

View all clinical trial activity →

• What is CORCEPT THERAPEUTICS?

  Corcept Therapeutics is a pharma organization headquartered in Redwood City, USA. It trades on NYSE under ticker CORT. Primary therapeutic focus areas include Nonalcoholic Steatohepatitis (NASH), Amyotrophic Lateral Sclerosis, Cushing's Syndrome, Cushing Syndrome, Hepatic Impairm

• Is CORCEPT THERAPEUTICS publicly traded?

  Yes. CORCEPT THERAPEUTICS is listed with ticker CORT on NYSE per SEC EDGAR records linked on this profile.

• What drugs does CORCEPT THERAPEUTICS develop or market?

  We link 36 drug profile(s) where CORCEPT THERAPEUTICS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/corcept-therapeutics-inc#company-drugs.

• What are the latest developments for CORCEPT THERAPEUTICS?

  In the last 12 months our linked public records show 67 trial program update(s) and 3 US patent grant(s) tied to this profile.

• What therapeutic areas does CORCEPT THERAPEUTICS focus on?

  CORCEPT THERAPEUTICS focuses on Nonalcoholic Steatohepatitis (NASH), Amyotrophic Lateral Sclerosis, Cushing's Syndrome based on our analysis of their pipeline programs and drug development activities.